- PLN259.61m
- PLN202.79m
- PLN1.31m
- 22
- 11
- 32
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.65 | ||
| Price to Tang. Book | 4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 198.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.44% | ||
| Return on Equity | -12.91% | ||
| Operating Margin | -1669.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 0 | 124.91 | 1.17 | 1.61 | 1.31 | 52.7 | 16.2 | 237.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oncoarendi Therapeutics SA is a Poland-based biopharmaceutical company . The Company is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Company's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The Company has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
Directors
- Marcin Szumowski CMG (50)
- Mariusz Gromek VSU
- Slawomir Broniarek FID
- Marta Borkowska COO
- Adam Golebiowski VPR
- Karolina Dzwonek VPR
- Jacek Olczak VPR
- Nicolas Beuzen VBD
- Pawel Dobrzanski SDR
- Slawomir Broniarka MGB
- Agnieszka Rajczuk - Szczepanska MGB
- Zbigniew Zasla MGB
- Henryk Gruza SUB
- Rafal Kaminski SUB
- Tomasz Pieiec SUB
- Paul Van Der Horst SUB
- Nancy Van Osselaer SUB
- Piotr Zolkiewicz SUB (35)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 4th, 2017
- Public Since
- April 19th, 2018
- No. of Employees
- 111
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Warsaw Stock Exchange- Shares in Issue
- 16,836,000
- Address
- Zwirki I Wigury 101, WARSZAWA, 02-089
- Web
- https://molecure.com/
- Phone
- +48 225526724
- Contact
- Michal Wierzchowski
- Auditors
- UHY ECA Audyt Sp. Zoo SP. k.
Upcoming Events for MOC
Similar to MOC
Airway Medix SA
Warsaw Stock Exchange
Bioton SA
Warsaw Stock Exchange
Braster SA
Warsaw Stock Exchange
Captor Therapeutics SA
Warsaw Stock Exchange
E-Shopping SA
Warsaw Stock Exchange
FAQ
As of Today at 19:14 UTC, shares in Molecure SA are trading at PLN15.42. This share price information is delayed by 15 minutes.
Shares in Molecure SA last closed at PLN15.42 and the price had moved by -28.78% over the past 365 days. In terms of relative price strength the Molecure SA share price has underperformed the FTSE Global All Cap Index by -36.44% over the past year.
The overall consensus recommendation for Molecure SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Molecure SA does not currently pay a dividend.
Molecure SA does not currently pay a dividend.
Molecure SA does not currently pay a dividend.
To buy shares in Molecure SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN15.42, shares in Molecure SA had a market capitalisation of PLN259.61m.
Here are the trading details for Molecure SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: MOC
Based on an overall assessment of its quality, value and momentum Molecure SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Molecure SA is PLN25.60. That is 66.02% above the last closing price of PLN15.42.
Analysts covering Molecure SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Molecure SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -24.77%.
As of the last closing price of PLN15.42, shares in Molecure SA were trading -17.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Molecure SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN15.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Molecure SA's management team is headed by:
- Marcin Szumowski - CMG
- Mariusz Gromek - VSU
- Slawomir Broniarek - FID
- Marta Borkowska - COO
- Adam Golebiowski - VPR
- Karolina Dzwonek - VPR
- Jacek Olczak - VPR
- Nicolas Beuzen - VBD
- Pawel Dobrzanski - SDR
- Slawomir Broniarka - MGB
- Agnieszka Rajczuk - Szczepanska - MGB
- Zbigniew Zasla - MGB
- Henryk Gruza - SUB
- Rafal Kaminski - SUB
- Tomasz Pieiec - SUB
- Paul Van Der Horst - SUB
- Nancy Van Osselaer - SUB
- Piotr Zolkiewicz - SUB